Abstract
In this chapter, we will review the epidemiology, clinical phenotype, genetics, causes, and management of amyotrophic lateral sclerosis (ALS). ALS is a devastating and invariably fatal adult-onset neurodegenerative disorder. It remains incurable, killing about 1,200 people in the UK each year. It has an annual incidence of 1–2 per 100,000, a figure that appears to be consistent in most populations studied around the world. ALS is also known as “Lou Gehrig’s disease” in the USA and motor neuron disease (MND) in the UK.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Further Reading
Andersen PM, Borasio GD, Dengler R et al (2007) Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 8:195–213
Brooks BR, Miller RG, Swash M, Munsat TL et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 1:293–299
Daube JR (2000) Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 23:1488–1502
Kanning KC, Kaplan A, Henderson CE (2010) Motor neuron diversity in development and disease. Annu Rev Neurosci 33:409–440
Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955
Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19:R46–R64
Leigh PN, Wijesekera LC (2010) Motor neuron disease: focusing the mind on ALS: updated practice parameters. Nat Rev Neurol 6:191–192
Miller RG, Jackson CE, Kasarskis EJ et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227–1233
Radunovic A, Mitsumoto H, Leigh PN (2007) Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 6:913–925
Rowland LP (2001) How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 58:512–515
Sreedharan J (2010) Neuronal death in Amyotrophic Lateral Sclerosis (ALS): what can we learn from genetics? CNS Neurol Disord Drug Targets 9:259–267
Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8:94–109
Zinman L, Cudkowicz M (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 10:481–490
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this entry
Cite this entry
Leigh, P.N., Sreedharan, J., Wijesekera, L. (2013). Motor Neuron Disease: Amyotrophic Lateral Sclerosis. In: Pfaff, D.W. (eds) Neuroscience in the 21st Century. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1997-6_111
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1997-6_111
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1996-9
Online ISBN: 978-1-4614-1997-6
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences